AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...